ACC: Merck anacetrapib reveal bodes neutral at best for DalCor’s dalcetrapib

Pfizer, Roche, Lilly and finally, Merck. One by one, they ended their CETP inhibitor programs, giving up the ghost on a once-vaunted class of cholesterol-targeting drugs thought to be a potential game-changer for heart disease. In spite of the mass exodus, little DalCor Pharmaceuticals emerged in 2015, with the Roche castoff dalcetrapib and a goal to succeed where the heavy hitters of Big Pharma had failed.